Skip to content

Mystical experience

Profound states of unity and self-transcendence, and their measured role as mediators of therapeutic outcomes.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Mystical experience, mystical-type experience, ego dissolution, unitive experience, peak experience, then ranked by relevance.

Research consistently shows that classic psychedelics like psilocybin can reliably occasion mystical-type experiences, characterized by unity, noetic quality, sacredness, positive mood, transcendence of time/space, and ineffability. These experiences are robustly associated with enduring positive changes in well-being, personality (increased openness), and therapeutic outcomes for conditions such as cancer-related distress, depression, anxiety, and addiction, with the mystical experience often mediating these benefits. However, most studies have small, homogeneous samples and many are open-label, limiting generalizability and causal certainty.

Confidence in the evidence

Moderate
  • Multiple double-blind RCTs and a systematic review consistently show psilocybin can induce mystical experiences and that these experiences predict positive outcomes.
  • Sample sizes are generally small (e.g., 18–36 in key experimental studies, 29 in the cancer RCT), limiting statistical power and generalizability.
  • Several studies are open-label or lack active placebo controls, increasing risk of expectancy bias.
  • The evidence is highly consistent in direction across diverse designs (RCTs, observational, qualitative) and populations (healthy volunteers, patients with cancer, smokers).
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016
Supports

Psilocybin produced immediate and sustained improvements in anxiety and depression, and the psilocybin-induced mystical experience mediated these therapeutic effects.

RCT · Sample size: 29

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 2011
Supports

Psilocybin at 20 and 30 mg/70 kg produced mystical-type experiences in 72% of volunteers, with persisting positive changes in attitudes, mood, and behavior at 14 months.

RCT · Sample size: 18

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness 2011
Supports

Psilocybin-occasioned mystical experiences led to significant increases in the personality domain of Openness that remained elevated more than 1 year later.

RCT

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later 2008
Supports

At 14-month follow-up, 58% rated the psilocybin experience among the five most personally meaningful and 67% among the five most spiritually significant experiences of their lives, with mystical experience mediating these ratings.

RCT · Sample size: 36

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin 2015
Supports

The MEQ30 was validated and latent variable scores positively predicted persisting changes in attitudes, behavior, and well-being attributed to psilocybin.

observational · Sample size: 184

Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. 2016
Unclear

Increased global functional connectivity correlates with LSD-induced ego dissolution.

observational

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors 2017
Supports

High-dose psilocybin produced greater acute and persisting effects than low-dose, with large positive changes in interpersonal closeness, gratitude, life meaning, and other measures at 6 months, mediated by mystical experience and meditation practice.

RCT · Sample size: 75

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. 2019
Supports

Classic psychedelics occasion mystical experiences characterized by a strong sense of unity, and naturalistic use is associated with positive mental health and prosocial outcomes.

review

Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction 2015
Supports

80% of participants demonstrated biologically verified smoking abstinence at 6 months, and abstainers scored significantly higher on mystical experience, suggesting a mediating role.

observational · Sample size: 15

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin 2012
Supports

Factor analysis of the MEQ revealed a four-factor structure (unity/noetic/sacredness, positive mood, transcendence of time/space, ineffability) with good reliability and validity.

observational · Sample size: 1602

Religious and Mystical Experiences as Artifacts of Temporal Lobe Function: A General Hypothesis 1983
Unclear

Mystical and religious experiences are hypothesized to be evoked by transient electrical microseizures within deep structures of the temporal lobe.

theoretical

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review 2022
Supports

10 of 12 studies found a significant association between mystical experience and symptom reduction in psychedelic therapy for cancer-related distress, substance use disorder, and depression.

review

Self unbound: ego dissolution in psychedelic experience 2017
Unclear

Ego dissolution is explained by predictive processing principles, suggesting the self-model is a useful fiction that does not correspond to a real entity.

theoretical

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. 2018
Unclear

Classic hallucinogens and mystical experiences: phenomenology and neural correlates.

review

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? 2015
Supports

Evidence suggests a relationship between subjective experiences (peak experiences, afterglow) and therapeutic success with psychedelics.

review

Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study 2026
Supports

Greater therapeutic gains followed ketamine sessions with higher mystical experience scores, and the patient attributed improvements to the psychological and spiritual impact.

qualitative · Sample size: 1

How People Describe Their Mystical Experiences: Analyzing Language, Narrative, and Digital Expression 2026
Mixed

Social media users share detailed narratives of mystical experiences, challenging the notion of ineffability, and community identity shapes how experiences are framed.

observational

The Architecture of Ego Dissolution: A Mechanical-First Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A Interfaces 2026
Unclear

Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A interfaces.

theoretical

Optimizing music for psychedelic-assisted therapy: Examining contemporary practices, traditional entheogenic rituals, and musically-induced peak experiences 2026
Unclear

Conflicting musical features across modern PAT, traditional rituals, and musically-induced peak experiences suggest music should be tailored to the drug, individual, and desired experience.

review

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings. 2026
Supports

Six of eight subscales of the English Psychedelic Experience Scale (including mystical factors) show high internal consistency, supporting the factor structure.

observational · Sample size: 280

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality 2026
Unclear

Relations between DMT, psychosis model, therapy model, and mystical experiences and positive emotionality.

theoretical

On the ineffability and the noetic quality of mystical experiences 2026
Unclear

Using Wittgenstein's framework, mystical experiences are placed outside the limits of language, but have pragmatic and subjective value for religious life.

theoretical

A cross-sectional survey on depersonalization/derealization and meditation-induced alterations of the self. 2026
Mixed

Meditation-induced DPDR-like states are phenomenologically similar but experienced as more positive and spiritually meaningful than those from trauma or cannabis.

observational · Sample size: 121

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption. 2026
Supports

State of Surrender, experiential acceptance, cognitive defusion, and present-moment awareness emerged as robust predictors of mystical experiences.

observational · Sample size: 150

Understanding mystical experiences through the lens of entropy: introduction to the special issue on ‘mystical entropy’ 2026
Unclear

Introduction to a special issue on 'mystical entropy'.

theoretical

Points of agreement

  • Psilocybin and other classic psychedelics can reliably induce mystical-type experiences in controlled settings.
  • Mystical experiences are consistently associated with enduring positive changes in well-being, attitudes, and behavior.
  • The mystical experience often mediates therapeutic outcomes in conditions like anxiety, depression, and addiction.
  • The MEQ30 is a validated and reliable tool for measuring mystical experiences.

Conflicts

  • One study suggests mystical experiences may be artifacts of temporal lobe microseizures, while others treat them as psychologically meaningful and therapeutic.
  • The role of ineffability is contested: some studies find detailed narratives online, while philosophical analysis argues mystical experiences lie outside language.
  • Music features that optimize mystical experiences in PAT differ from those in traditional rituals and musically-induced peak experiences.

Gaps

  • Most studies have small, homogeneous samples lacking diversity in gender, ethnicity, and socioeconomic status.
  • Many studies are open-label or lack active placebo controls, increasing risk of bias.
  • Long-term durability of effects beyond 14 months is rarely assessed.
  • Predictors of mystical experience intensity and methods to minimize anxiety during sessions are underexplored.
  • The neural mechanisms underlying mystical experiences are not fully characterized.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Mystical experience, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Mystical experience or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

1,437 articles · 480 from the last two years · 799,407 participants across 502 studies reporting sample size

Common study designs

review 115 qualitative study 50 observational cohort 70 cross-sectional survey 71 theoretical or philosophical paper 441

Research

Synthesize the evidence → Search all →

Shared Neurobiological and Computational Mechanisms of Psychedelic, Contemplative, and Fasting-Induced Mystical Experience

Alex Jinich-Diamant preprint

Mystical states induced by psychedelics, meditation, or fasting all converge on the same brain state: a transient near-critical regime. Serotonergic psychedelics relax top-down priors by sensitizing layer 5 pyramidal neurons; open-monitoring meditation elevates cortical entropy through altered thalamocortical connectivity; caloric restriction destabilizes the default mode network by attenuating metabolic support for high-level attractors. The depth of the mystical state, not the method of induction, predicts lasting therapeutic benefit, suggesting conscious experience itself is the mechanistic agent of change. This framework proposes that near-critical dynamics may allow field-theoretic and quantum-coherent contributions to consciousness to become detectable.

DOI: 10.31234/osf.io/km8hr_v2

Transdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance

Ágota Vass, Gábor Csukly, Kinga Farkas • 16 citations preprint

Autism spectrum disorder and schizophrenia share a disturbance in the minimal sense of self—a basic, pre-reflective awareness of being a subject of experience. This common feature cuts across diagnostic boundaries and may help explain overlapping symptoms. The authors propose a framework linking neural, cognitive, and phenomenological levels to study this self-disturbance. They argue that the neural correlates of minimal selfhood can be more reliably identified during meditation than during rest, because meditation amplifies present-focused inward attention while reducing reflective mind-wandering. This approach aligns with efforts to find biomarkers for psychopathology and to move beyond traditional diagnostic categories toward a model that takes self-experience seriously.

DOI: 10.31234/osf.io/vfuzh

ScholarOne - Limitless Experience through Limited Consumption: Psychedelics, Mystical Mindfulness, and Sustainable Corporate Leadership Development

Joshua Nunziato

Mindfulness, defined as non-focal awareness of consciousness itself, can be cultivated for corporate leadership development. Mystical mindfulness, integrating reflective mystical experience with everyday mindfulness, provides direct intuitive awareness of consciousness as an infinite source of experience mediated through finite bodies. A guided high-dose psychedelic trip can facilitate the insight that limited consumption—consistent with human health, equitable resource distribution, and biospheric regeneration—can enable limitless experiential opportunities. Decoupling tangible resource consumption growth from the growth of capabilities for producing and enjoying new experiences is possible and necessary. This recognition can orient leaders to create businesses addressing the unsustainability crisis.

DOI: 10.31124/advance.23710375

Can a Mystical Experience be Emulated by AI-Generated Rationality?

Mengjiao Yin

Artificial intelligence can evoke feelings of sacredness in people, but only under certain conditions. Spiritual believers report lower perceived sacredness, service quality, and trust when they know AI is involved, while non-believers show no such difference. Oral conversation enhances perceived sacredness compared to touch-screen interaction. The type of question asked—open-ended or closed-ended—does not significantly affect sacred experiences. AI cannot possess spirituality but can effectively evoke subjective sacred experiences through carefully designed interaction contexts.

DOI: 10.31235/osf.io/eyp9c_v1

Mystical Experience and Global Revolution

Mike Sosteric

Religion and spirituality, often dismissed as reactionary or illusory since Marx, contain an authentic revolutionary core. Drawing on biographical examples, the paper argues that human spirituality is not a primitive holdover but essentially revolutionary. In the face of escalating global ecological, political, and economic crises, this core must be examined, recovered, and embraced as part of local and global strategies for transformation.

DOI: 10.31235/osf.io/ah45u

PHARMACOKINETICS OF N,N-DIMETHYLTRYPTAMINE FUMARATE IN HUMANS

Meghan Good, Tiffanie Benway, Zelah Joel et al. • 4 citations

DMT (N,N-dimethyltryptamine) is being developed as a treatment for major depressive disorder. In a phase I trial, 24 healthy adults received escalating intravenous doses of DMT fumarate (SPL026) that were safe and well-tolerated. DMT exposure increased proportionally with dose over the 9–21.5 mg range. Peak plasma concentration occurred at about 10 minutes, and the mean elimination half-life was 9–12 minutes. In vitro experiments showed that DMT is cleared by monoamine oxidase A (MAO-A) and modified by the enzymes CYP2D6 and CYP2C19. The unbound fraction of DMT in plasma was approximately 70%. These findings support the development of DMT infusion regimens for treating major depressive disorder.

DOI: 10.22541/au.165237523.39763980/v1

Ketamine-induced pleasant but not unpleasant dissociation is linked to the functional connectivity profile of the posteromedial cortex

Zumrut Duygu Sen, Nitin Sharma, Lena Vera Danyeli et al. preprint

Ketamine causes temporary dissociative experiences alongside its rapid therapeutic effects. This study examined whether pleasant and unpleasant dissociations can be predicted by functional connectivity of the posteromedial cortex (PMC) in 35 male participants during ultrahigh-field MRI. Pleasant dissociation (oceanic boundlessness) was predicted by PMC connections with control network regions at baseline and during infusion, and additionally with default mode network regions during infusion. Unpleasant dissociation (anxious ego dissolution) could not be predicted by PMC connectivity. The findings suggest distinct brain mechanisms for pleasant versus unpleasant dissociations, and that PMC connectivity changes may be a shared neural feature of dissociation from both ketamine and psychedelics.

DOI: 10.31234/osf.io/eadr2

La realidad fundamental y la experiencia mística.

Jorge Eduardo Pacheco Fuenzalida

Mystical experience is a profound, boundary-crossing encounter with reality in which human consciousness transcends ordinary concepts. Such experience suggests that beneath physical phenomena lies a fundamental, unified order where the everyday fragmentation between mind and matter is insubstantial. This view finds a theoretical framework in neutral monism and double-aspect monism, which posit that fundamental reality (the ontic state) is inaccessible through ordinary observation. Only through mystical experience can one penetrate this reality; otherwise, we access only the partial, local manifestations of the mental and physical (epistemic states).

DOI: 10.29393/tmudec-56pj1rf56 Mysticism spiritual experiences Mystical states Spiritual insights Enlightenment +20

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.

Journal of affective disorders • November 1, 2026 • Carlton M Kelly, Mathieu Fradet, Catherine M Bostian et al.

A single 25-mg dose of psilocybin with psychological support was associated with sustained improvements in anxiety, quality of life, functioning, and PTSD symptoms in 15 veterans with treatment-resistant depression. Anxiety scores dropped 59% from baseline at three weeks and remained lower through 12 months. Quality of life increased 24% and functional impairment decreased 46% at three weeks, though these effects were no longer statistically significant after accounting for concurrent improvements in depression. PTSD symptom reductions were observed at all timepoints. Acute subjective experiences did not correlate with treatment response. The study is limited by its small sample and open-label design.

DOI: 10.1016/j.jad.2026.122063 Full text Anxiety Posttraumatic stress disorder Psilocybin Treatment-resistant depression +1

A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.

The International journal on drug policy • August 1, 2026 • Myfanwy Graham, Yimin Ge, Rosalie Liccardo Pacula et al. • 1 citation

An estimated 19% of adults in Canada, the United States, Australia, and New Zealand have used psilocybin, LSD, MDMA, or ketamine at some point in their lives. Psilocybin was the most commonly used substance, with lifetime use highest in Canada (16.3%), followed by the US (13.0%) and New Zealand (12.1%), and lowest in Australia (7.8%). Among those who had ever used a psychedelic, 10-20% had asked their medical provider about medical use, and over a third of past-year users reported experiencing an adverse health effect. Past-month use was low across all countries. Consumer interest in therapeutic use has outpaced clinical trials and therapeutic provisions, and many people use these substances outside regulated pathways, which may increase the risk of adverse events.

DOI: 10.1016/j.drugpo.2026.105348 Full text Adverse events Drug policy Nonmedical use Psychedelics

Clinical trials

All Mystical experience trials →